reports
Sunrun Inc: 1 director
A director at Sunrun Inc sold 50,000 shares at 18.595USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Sunrun Builds the Nation’s Largest Distributed Power Plant After Quint...
Sunrun Builds the Nation’s Largest Distributed Power Plant After Quintupling Customer Participation in 2025 Sunrun scales the nation’s largest distributed power plant with 400% growth, 17 programs, major partnerships, and record grid dispatches as AI-driven electricity demand surges SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- With rising electricity costs, growing risk of power outages, and a widening gap between power supply and demand, Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, rapidly delivered new, dispatchabl...
Sunrun Announces Date for Fourth Quarter and Full-year 2025 Earnings R...
Sunrun Announces Date for Fourth Quarter and Full-year 2025 Earnings Report Earnings Release and Conference Call Scheduled for February 26, 2026 SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN) today announced that it will issue its fourth quarter and full-year 2025 earnings report after the market closes on Thursday, February 26, 2026. A conference call has been scheduled to discuss these earnings results at 1:30 p.m. Pacific Time. The conference call can be accessed live via the Sunrun Investor Relations website at or over the phone by dialing (877) 407-5989 (to...
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcar...
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Expects Operating Expenses of Between $210 Million and $2...
Snap Inc: 1 director
A director at Snap Inc sold/gave away 1,584,243 shares at 0.000USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare...
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025. The company’s presentation and participation in a fireside chat will begin at 2:15 p.m. PT/5:15 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be ...
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientif...
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes – Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific ...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equ...
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment ...
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia – Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for ...
Esperion to Participate in Piper Sandler 37th Annual Healthcare Confer...
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsperion...
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for t...
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for ...
Sunrun Earns Multiple No. 1 Rankings in Extel’s All-America Executive ...
Sunrun Earns Multiple No. 1 Rankings in Extel’s All-America Executive Team Survey Sunrun receives first-place recognitions across all categories in the Alternative Energy sector and is named a Most Honored Company, recognizing the Company’s excellence in executive leadership, corporate governance, and investor relations SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, today announced it has once again earned top honors in the 2025 Extel (formerly Institutional Investor) All-Am...
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of ...
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 – Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR Outcomes Reports Patients Who Took Bempedoic Acid Were 42% Less Likely to Experience Venous Thromboembolism Events Compared to Placebo – ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indi...
Sunrun Announces Appointment of Craig Cornelius to its Board of Direct...
Sunrun Announces Appointment of Craig Cornelius to its Board of Directors SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, today announced the appointment of Craig Cornelius as a member of Sunrun’s board of directors (the “Board”). Mr. Cornelius brings two decades of industry experience across the renewable energy space. “I am excited to announce the appointment of Craig as our newest board member. Craig brings a wealth of experience and perspective, having led large, complex e...
Sunrun Reports Third Quarter 2025 Financial Results
Sunrun Reports Third Quarter 2025 Financial Results Aggregate Subscriber Value of $1.6 billion in Q3, 10% growth year-over-year Contracted Net Value Creation of $279 million, 35% growth year-over-year Net change in cash and restricted cash of $144 million and Cash Generation1 of $108 million in Q3, the sixth consecutive quarter of positive Cash Generation Cash Generation guidance for 2025 of $250 million to $450 million narrowed within original range, $350 million midpoint reiterated SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America’s largest provider of h...
Esperion Reports Third Quarter 2025 Financial Results and Provides Bus...
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update – Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 2040 – – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidemias – – Partner Otsuka Received Regulatory Approval and Favorable Preliminary...
- Dan Salmon
Snap Inc. (SNAP, Neutral, $8 target) Revenue growth in-line, and Perpl...
What’s New: In this first take following tonight’s results, we focus on: 1. Stock pops on improved results and surprise Perplexity deal 2. DR recovers & continued enthusiasm for SMBs, but large advertisers down 3. North America DAUs steady but we remain cautious as age verification rolls out 4. Perplexity boosts the AI narrative 5. Very good cost control and margins
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Off...
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of John Harlow as the Company’s Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion’s Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. "We are thrilled to welcome John as our Chief Commercial Officer at suc...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
YNDX YANDEX NV CLASS A
WDC WESTERN DIGITAL CORPORATION
TTMI TTM TECHNOLOGIES INC.
RUN SUNRUN INC.
OSIS OSI SYSTEMS INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NWPX NORTHWEST PIPE CO.
MMSI MERIT MEDICAL SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LOCO EL POLLO LOCO HOLDINGS INC
KWR QUAKER CHEMICAL CORPORATION
HNRG HALLADOR ENERGY CO.
GALT GALECTIN THERAPEUTICS
EXPO EXPONENT INC.
BRKR BRUKER CORPORATION
AXTI AXT INC.
ASPN ASPEN AEROGELS
GASS STEALTHGAS
BJRI BJ'S RESTAURANTS INC.
AUP AURINIA PHARMACEUTICALS INC.
NVT NINH VAN BAY REAL ESTATE
ATEC ALPHATEC HOLDINGS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
FSLR FIRST SOLAR INC.
LPLA LPL FINANCIAL HOLDINGS INC.
TWLO TWILIO INC. CLASS A
HCC WARRIOR MET COAL INC.
BTU PEABODY ENERGY CORPORATION
NEXA NEXA RESOURCES S.A.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
OPXSD OPTEX SYSTEMS HOLDINGS INC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
TVTX TRAVERE THERAPEUTICS INC
AMR ALPHA METALLURGICAL RESOURCES INC
CGEM CULLINAN ONCOLOGY INC
MMED MIND MEDICINE MINDMED
MRVL MARVELL TECHNOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
NVTS NAVITAS SEMICONDUCTOR CORP
APG API GROUP CORP
JOBY JOBY AVIATION INC
SPXC SPX TECHNOLOGIES INC
IE IVANHOE ELECTRIC INC
AMPX AMPRIUS TECHNOLOGIES INC
DUOT DUOS TECHNOLOGIES GROUP INC
IMPP IMPERIAL PETE INC
LAES SEALSQ CORP
LXEO LEXEO THERAPEUTICS INC
METC RAMACO RESOURCES INC.
RAPP RAPPORT THERAPEUTICS INC
TOYO TOYO CO LTD
CLNN CLENE INC
FCEL FUELCELL ENERGY INC.
QUIK QUICKLOGIC CORP
GSAT GLOBALSTAR INC.
ACA ALDA CAPITAL CORP COM
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.